
(MedPage Today) — Adding a novel oral drug originally designed to treat celiac disease to standard treatment for post-COVID multisystem inflammatory syndrome in children (MIS-C) appeared safe and effective in a small, phase IIa randomized, double…
Source link : https://www.medpagetoday.com/infectiousdisease/covid19/116754
Author :
Publish date : 2025-07-30 20:49:00
Copyright for syndicated content belongs to the linked
Source.